Quarterly Financials | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 121 | 184 | 89 | 66 | 71 | 57 | 57 | 70 | 68 | 70 | 79 | 93 | 80 | 90 | 85 |
Expenses | 73 | 100 | 64 | 48 | 52 | 40 | 41 | 74 | 54 | 54 | 61 | 78 | 63 | 70 | 67 |
EBITDA  | 49 | 84 | 25 | 18 | 18 | 17 | 16 | -4 | 14 | 16 | 17 | 14 | 18 | 20 | 18 |
Operating Profit % | 40 % | 45 % | 28 % | 25 % | 26 % | 28 % | 27 % | -7 % | 20 % | 22 % | 21 % | 15 % | 22 % | 22 % | 21 % |
Depreciation | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 4 | 5 | 5 |
Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 2 |
Profit Before Tax  | 46 | 80 | 22 | 14 | 14 | 12 | 10 | -10 | 7 | 8 | 10 | 6 | 11 | 13 | 11 |
Tax | 11 | 21 | 6 | 4 | 4 | 2 | 3 | -2 | 2 | 2 | 2 | 2 | 3 | 4 | 3 |
Net Profit | 34 | 60 | 16 | 11 | 11 | 9 | 7 | -7 | 5 | 6 | 8 | 4 | 8 | 9 | 9 |
EPS in ₹ | 32.96 | 57.33 | 15.20 | 9.97 | 9.99 | 8.82 | 6.82 | -7.23 | 5.10 | 5.99 | 7.39 | 4.08 | 8.04 | 8.15 | 8.21 |
Above figures are in Rs. Crores Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Total Assets  | 37 | 51 | 71 | 96 | 105 | 133 | 166 | 341 | 354 | 394 |
Fixed Assets | 13 | 13 | 17 | 20 | 29 | 43 | 57 | 92 | 121 | 139 |
Current Assets | 25 | 38 | 53 | 75 | 75 | 89 | 106 | 228 | 207 | 243 |
Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 12 | 14 | 0 |
Investments | 1 | 2 | 3 | 5 | 4 | 3 | 4 | 0 | 0 | 0 |
Other Assets | 24 | 37 | 51 | 71 | 72 | 87 | 102 | 237 | 219 | 255 |
Total Liabilities  | 37 | 51 | 71 | 96 | 105 | 133 | 166 | 341 | 354 | 394 |
Current Liabilities | 17 | 27 | 42 | 62 | 61 | 68 | 78 | 140 | 126 | 152 |
Non Current Liabilities | 1 | 3 | 4 | 6 | 8 | 20 | 28 | 21 | 29 | 20 |
Total Equity  | 19 | 21 | 25 | 29 | 36 | 45 | 60 | 180 | 199 | 223 |
Reserve & Surplus | 15 | 17 | 20 | 19 | 27 | 36 | 51 | 171 | 190 | 214 |
Share Capital | 4 | 5 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Above figures are in Rs. Crores Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Net Cash Flow | 1 | 0 | 2 | -1 | -0 | 0 | 4 | 3 | -6 | -1 |
Investing Activities | -1 | -3 | -7 | -6 | -12 | -18 | -23 | -63 | -48 | -26 |
Operating Activities | 1 | -3 | 4 | -1 | 14 | 6 | 27 | 61 | 41 | 43 |
Financing Activities | 1 | 6 | 5 | 5 | -2 | 12 | 1 | 6 | 1 | -17 |
Above figures are in Rs. Crores % Holding | Mar 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Promoter | 54.13 % | 54.24 % | 54.24 % | 54.43 % | 54.45 % | 54.45 % | 54.45 % | 54.74 % | 54.74 % | 54.77 % | 54.77 % | 54.83 % | 54.83 % | 54.83 % | 54.83 % |
FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.00 % | 0.00 % | 0.02 % | 0.03 % |
Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
Public / Retail | 23.18 % | 25.38 % | 25.91 % | 26.29 % | 26.54 % | 26.25 % | 25.92 % | 26.27 % | 29.29 % | 31.64 % | 32.95 % | 31.70 % | 31.78 % | 32.78 % | 33.25 % |
Others | 22.69 % | 20.38 % | 19.84 % | 19.28 % | 19.01 % | 19.30 % | 19.63 % | 18.99 % | 15.96 % | 13.58 % | 12.27 % | 13.47 % | 13.40 % | 12.38 % | 11.90 % |
No of Share Holders | 148 | 168 | 379 | 581 | 1,049 | 4,198 | 5,376 | 6,211 | 6,943 | 6,291 | 5,786 | 5,695 | 5,273 | 7,487 | 8,947 |
Dividend Per Share (₹) | 0.00 | 0.6 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend Yield (%) | 0.00 | 1.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Closure of Trading Window
3 days ago Kwality Pharmaceutical Limited Receives Product Registration Of Cyclophosphamide 1Gm In Mexico
Feb 14, 2025 Announcement under Regulation 30 (LODR)-Newspaper Publication
Feb 04, 2025 Integrated Filing (Financial)
Jan 31, 2025 UNAUDITED FINANCIAL RESULTS FOR Q.E. 31-12-2024
Jan 31, 2025 Board Meeting Outcome for SUBMISSION OF UNAUDITED FINANCIAL RESULTS FOR Q.E. 31-12-2024
Jan 31, 2025 KWALITY PHARMA RECEIVED SFDA APPROVAL FOR ITS GENERAL INJECTABLES AND BETA LACTAM (UNIT 1 & 2 IN AMRITSAR).
Jan 21, 2025 Board Meeting Intimation for Declaring Standalone And Consolidated Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024 Along With Limited Review Report
Jan 20, 2025 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Jan 12, 2025 Kwality Pharmaceutical Ltd Receives RCGM Approval To Advance For Pre-Clinical Studies Of Erythropoietin (10000 IU/Ml)
Jan 02, 2025 Intimation Under Regulation 30(6) Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015 ('SEBI Listing Regulations') - Schedule Of Analyst/ Institutional Investor Meeting
Nov 27, 2024 Kwality Received Its First Biological Product Permission For Manufacturing And Sale Of Pegylated-Asparaginase
Nov 26, 2024 Kwality Pharma Received The Approval For Leuprorelin Acetate For Injectable Suspension As A Site Variation From Greece
Nov 06, 2024 Announcement under Regulation 30 (LODR)-Newspaper Publication
Nov 06, 2024 Board Meeting Outcome for Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2024
Oct 30, 2024 Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2024
Oct 30, 2024 Board Meeting Intimation for Consider And Approve The Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2024.
Oct 22, 2024 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Oct 11, 2024 Closure of Trading Window
Sep 29, 2024 Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Sep 26, 2024 Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Sep 26, 2024 Proceedings Of 41St Annual General Meeting Of The Company Held On September 24, 2024
Sep 24, 2024 Announcement under Regulation 30 (LODR)-Newspaper Publication
Sep 04, 2024 Reg. 34 (1) Annual Report.
Aug 31, 2024 Notice Of 41St Annual General Meeting Of The Company
Aug 31, 2024 41St Annual General Meeting (AGM) Of The Company Will Be Held On Tuesday, The 24Th September, 2024 At 12.00 Noon Through Video Conference (VC) / Other Audio Visual Means (OAVM)
Aug 31, 2024 Intimation Of Book Closure
Aug 31, 2024 Board Meeting Outcome for Intimation Of AGM
Aug 31, 2024 Clarification On Price Movement
Aug 23, 2024 Clarification sought from Kwality Pharmaceuticals Ltd
Aug 22, 2024 Announcement under Regulation 30 (LODR)-Newspaper Publication
Aug 13, 2024 Rectification Of Typographical Error And Submission Of Revised Financial Results For The Quarter Ended 30Th June 2024
Aug 12, 2024 Submission Of Standalone And Consolidated Un-Audited Financial Results For The Quarter Ended On 30.06.2024
Aug 10, 2024 Board Meeting Outcome for Submission Of Standalone And Consolidated Un-Audited Financial Results For The Quarter Ended On 30.06.2024
Aug 10, 2024 Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended On 30Th June, 2024
Aug 02, 2024 KWALITY PHARMA RECEIVED PERU- DIGEMID Approval For Its Generic, Injectable & OSD (Unit -1 In Amritsar) And Oncology, Injectable And OSD (Unit-3 In Himachal Pradesh)
Jul 17, 2024 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Jul 14, 2024 Closure of Trading Window
Jun 28, 2024 Compliances-Reg.24(A)-Annual Secretarial Compliance
May 30, 2024 Announcement under Regulation 30 (LODR)-Newspaper Publication
May 27, 2024 Investor Presentation Of The Results Of The Company For The Financial Year Ended 31St March, 2024
May 27, 2024 Investor Presentation Of The Results Of The Company For The Financial Year Ended 31St March, 2024
May 27, 2024 Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended 31St March, 2024
May 23, 2024 FINANCIAL RESULTS FOR THE QTR AND YEAR ENDED 31ST MARCH 2024
May 23, 2024 Board Meeting Intimation for Considering The Standalone & Consolidated Audited Financial Results For The 4Th Quarter And Financial Year Ended On 31St March, 2024
May 08, 2024 Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) For The Year Ended On 31St March, 2024
Apr 30, 2024 KWALITY PHARMA RECEIVED INVIMA APPROVAL FOR ITS ONCOLOGY (UNIT-III) VIAL LINE AND TABLET LINE
Apr 29, 2024 KWALITY PHARMA RECEIVED INVIMA APPROVAL FOR ITS AMPOULE AND VIAL PRODUCT LINES
Apr 22, 2024 Compliance Certificate For The Year Ended On 31St March, 2024
Apr 12, 2024 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Apr 12, 2024 RSI(14)

Neutral
67.92
ATR(14)

Volatile
59.76
STOCH(9,6)

Overbought
80.12
STOCH RSI(14)

Overbought
99.15
MACD(12,26)

Bullish
28.68
ADX(14)

Strong Trend
30.42
UO(9)

Bearish
54.85
ROC(12)

Uptrend And Accelerating
33.14
WillR(14)

Overbought
-15.83